Invitrogen™ CD56 (NCAM) Recombinant Mouse Monoclonal Antibody (CMSSB), Invitrogen™

Description

Recombinant antibodies are produced using specific genes that code for the desired antibodies. These genes are cloned into an expression vector and expressed in vitro. The advantages of recombinant antibodies include better specificity and lot-to-lot consistency. Applications Tested: This CMSSB clone has been tested for immunocytochemistry at 10 μg/mL and for flow cytometry at 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

CD56, also known as neural cell adhesion molecule (NCAM), is a highly glycosylated transmembrane glycoprotein of the immunoglobulin family. It plays a crucial role in cell adhesion, migration, axonal growth, pathfinding, and synaptic plasticity. CD56 is ubiquitously expressed in the nervous system in isoforms ranging from 120-180 kDa and is involved in homotypic adhesion of neural cells. It mediates interactions by binding extracellular matrix components such as laminin and integrins, with polysialic modification reducing CD56-mediated adhesion. In the hematopoietic system, CD56 is expressed on natural killer (NK) cells and a subset of T cells known as NKT cells. It is also found on most neuroectodermal-derived cell lines, tissues, and neoplasms, including retinoblastoma, medulloblastoma, astrocytomas, and neuroblastoma. CD56 serves as a widely used neuroendocrine marker with high sensitivity for neuroendocrine tumors and ovarian granulosa cell tumors. Diseases associated with CD56 dysfunction include rabies and blastic plasmacytoid dendritic cell neoplasms, highlighting its importance in both neural and immune system functions.